ABOS News and Press, Acumen Pharmaceuticals Inc. From 11/02/21

ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first patient in INTERCEPT-AD in October 2021 and enrollment of patients with ...

ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Enrollment of early Alzheimer’s patients is ongoing in INTERCEPT-AD, the Phase 1 placebo-controlled,...

Are These Top Biotech Stocks Worth Buying This Week? When considering which stocks to invest in amidst current stock market conditions, most would look towards the health care sector. Among biotech stocks, one subsection, in particular, continues to make headlines. That is t...

Gainers: ZIOPHARM Oncology (NASDAQ:ZIOP) +39%, RenovoRx (NASDAQ:RNXT) +17%, Sigilon Therapeutics (NASDAQ:SGTX) +17%, Acumen Pharmaceuticals (NASDAQ:ABOS) +15%, NeuroOne Medical Technologies (NASDAQ:NMTC) +7%. Losers: CorMedix (NASDAQ:CRMD) -25...

As September started, the healthcare stocks in the S&P 500 returned to post gains after a brief decline last week. Thanks mainly to health insurers, the S&P 500 Healthcare Sector Index posted the biggest one-day gain in more than two weeks on Thursday. Becoming the second-best pe...

Acumen Pharmaceuticals (NASDAQ:ABOS): Q2 EPS of -$141.93 may not be comparable to consensus of -$4.56. Cash Balance. Cash, cash equivalents and marketable securities were $68.8 million as of June 30, 2021, compared to $43.8 million as of December 31, 2020. Press Release For further details ...

Acumen’s investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trials Initiated ACU-001, a multi-center, randomized, double-blind, placebo-contro...

We have witnessed a record last week, with 19 launched IPOs and almost $10 billion raised. That is the most companies in one week since 2004. Even more, the NYSE floor which has been rather quiet in the past year came back to life. SPACs have been favored for a good part of 2020 and the beg...

Last week turned out to be the busiest IPO week since 2004. Nearly $10 billion was raised in 19 public offerings. DiDi Global (NYSE: DIDI), a Chinese ride-hailing app with 15 million drivers across 4,000 towns and cities, led the way by raising $4.4 billion at a $70.4 billion market cap. Se...

In the US IPO market’s busiest week since 2004, 19 IPOs raised nearly $10 billion, led by Chinese ride-hailing giant DiDi Global. Cybersecurity platform SentinelOne (S) upsized and priced above the upwardly revised range to raise $1.2 billion at a $10.6 billion market cap....